Best Practices in Chronic Myeloid Leukemia: Advances in Treatment & Management Strategies

Best Practices in Chronic Myeloid Leukemia (CML): Advances in Treatment & Management Strategies is organized by Specialty Pharma Education Center (SPEC).

Available Until: 6/20/2022

Accreditation:
Pharmacist continuing education credit
Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test (score of 70% or higher). Participants will have 3 opportunities to pass the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Accreditation Period: June 20, 2019 - June 20, 2022

Nursing continuing education credit
Educational Review Systems is an approved provider of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.

Accreditation Period: June 18, 2019 - June 18, 2021

Learning Objectives:
After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Oncology Pharmacists, Oncology Nurses, and Nurses
• Discuss the clinical relevance of risk stratification and molecular monitoring
• Recognize the first- and second-generation tyrosine kinase inhibitors (TKIs) available for the treatment of chronic myeloid leukemia (CML)
• Describe safety and efficacy profiles for TKIs
• Discuss the importance of monitoring treatment response and resistance
• Describe treatment strategies for patients who have become treatment resistant or treatment intolerant during the course of therapy
• Review new data on the safety and efficacy of current and emerging agents and combinations, mechanisms of action, molecular targets, and routes of administration to improve CML patient outcomes